GlassScriptPhysician profile
Peter C Lascarides
NPI 1316227325
$7,791.31
in general payments reported to CMS, 2019-2025
39 companies · $167 in 2025
The $167 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $796 · 2020: $1,174 · 2021: $771 · 2022: $776 · 2023: $1,735 · 2024: $2,373 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,500 · Food and Beverage: $1,457 · Travel and Lodging: $318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,500.00 |
| Food and Beverage | $1,457.32 |
| Travel and Lodging | $317.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $2,500.00 | 2023-2024 | |
| Boston Scientific Corporation | $1,421.31 | 2020-2025 | Wavewriter Alpha Prime 16, Intracept |
| Relievant Medsystems, INC. | $469.47 | 2019-2023 | Intracept |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $333.40 | 2020-2024 | Relistor |
| Nevro Corp. | $304.02 | 2020 | |
| Collegium Pharmaceutical, INC. | $303.70 | 2019-2021 | |
| Medtronic, INC. | $243.71 | 2021-2023 | Intellis Adaptivestim |
| Avanos Medical | $231.29 | 2019-2021 | |
| Stimwave Technologies Incorporated | $199.36 | 2020 | |
| Si-Bone, INC. | $164.59 | 2020 | |
| Grt US Holding, INC. | $161.11 | 2021-2022 | |
| Averitas Pharma INC. | $145.57 | 2023 | Qutenza |
| Nalu Medical, INC. | $125.88 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $121.46 | 2025 | |
| Abbott Laboratories | $113.29 | 2021-2023 | Proclaim |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $92.95 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.76 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $79.14 | 2019 | |
| Acelrx Pharmaceuticals, INC. | $77.48 | 2020 | |
| Redhill Biopharma INC. | $67.16 | 2020-2021 | |
| Epimed International, INC | $60.38 | 2019 | |
| Pfizer INC. | $53.14 | 2020-2021 | |
| Biodelivery Sciences International, INC. | $52.81 | 2019-2021 | |
| Allergan, INC. | $45.98 | 2021 | |
| Stryker Corporation | $42.98 | 2021 | |
| Medtronic USA, INC. | $37.83 | 2019 | |
| Virtus Pharmaceuticals LLC | $34.05 | 2021 | |
| Shionogi INC | $30.05 | 2019 | |
| Abbvie INC. | $27.09 | 2025 | |
| Intercept Pharmaceuticals, INC. | $21.35 | 2020 | |
| Depuy Synthes Sales INC. | $18.55 | 2020 | |
| Amgen INC. | $18.03 | 2019 | |
| Assertio Therapeutics, INC. | $17.76 | 2019 | |
| Ibsa Pharma INC. | $17.38 | 2021 | |
| Spinal Simplicity, LLC | $17.05 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $16.90 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.57 | 2020 | |
| Forte Bio-Pharma LLC | $12.12 | 2021 | |
| Spr Therapeutics, INC | $8.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Lascarides listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.